VivoSeq
Immunology

Subacute Cutaneous Lupus Erythematosus

3

Pipeline Programs↗

3

Active Trials↗

2

Companies Involved↗

Subacute Cutaneous Lupus Erythematosus is an early-stage landscape with 3 programs across 2 companies. The most active players are Eli Lilly, Biogen. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 2Biogen logo

Biogen

2 programs

Phase 3

Pipeline

Programs by Phase

Preclinical1

Litifilimab

Biogen

Phase 1
No programs
Phase 21

IMVT-1402

Immunovant Sciences GmbH

Phase 31

BIIB059

Biogen

Approved
No programs

Analysis

Modality Breakdown

67%

Small molecule

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSMonoclonal antibody133%

Small molecule leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 75% of 4 pipeline programs.

Analysis

Trial Status

3

clinical trials

Active, not recruiting2 · 67%
Enrolling by invitation1 · 33%

Clinical Trials

Trial Activity

A Multicenter, Open-Label, Single-Arm, Phase 3, Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adult Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy
Enrolling by invitation·Biogen logoBiogen·Phase 3·NCT06044337·306 enrolled
A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)
Active, not recruiting·Biogen logoBiogen·Preclinical·NCT05531565·450 enrolled
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations
Active, not recruiting·IImmunovant Sciences GmbH·Phase 2·NCT06980805·56 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)